jRCT2031200142已完成不适用
A double-blind, placebo-controlled study of HP-5070 in patients with primary hyperhidrosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 260
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 12age old over 至 No limit（—）
- 性别
- All
入选标准
- •Japanese patients aged 12 years or older
- •Patients with a diagnosis of primary local hyperhidrosis
- •Patients with involvement of palmar sites
排除标准
- •Patients with secondary hyperhidrosis
- •Patients with heavy sweating due to climacteric disturbance
- •Patients who have undergone surgery for hyperhidrosis (sympathectomy, nerve block, laser surgery, etc.)
结局指标
主要结局
-
The proportion of responders with the defined volume of sweat
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or IIHereditary AngioedemajRCT2051220178KalVista Pharmaceuticals, Ltd.12
进行中（未招募）
不适用
A Phase 3 Study in Moderate to Severe Rheumatoid ArthritisModerately to severely active rheumatoid arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-002339-27-BEEli Lilly and Company660
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of PirfenidonePatients with Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-000564-14-GBInterMune International AG.122
进行中（未招募）
1 期
A Phase 3 Study in Moderate to Severe Rheumatoid ArthritisModerately to severely active rheumatoid arthritisMedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-002339-27-GBEli Lilly and Company684
进行中（未招募）
1 期
A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with Hereditary Angioedema.EUCTR2021-001226-21-NLKalVista Pharmaceuticals Ltd114